Vonjo indication?

See the DrugPatentWatch profile for Vonjo

What is Vonjo (vonoprazan) used for?

Vonjo (vonoprazan) is an oral medicine used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation: FLT3 (FLT3-mutated disease). [1]

Which “indication” does Vonjo specifically cover for patients with AML?

The indication is tied to relapsed or refractory FLT3-mutated AML. That means it is meant for people whose AML has come back after treatment or has not responded to treatment, where testing shows an FLT3 mutation. [1]

Who qualifies based on the FLT3 mutation?

Patients need to have an FLT3 mutation in addition to being in the relapsed or refractory setting. If a patient does not have an FLT3 mutation, Vonjo would not match the stated indication. [1]

Is Vonjo the same as “Vonjo indication” people might search as “Vorjo/Vonjo” mix-ups?

Some searches for “Vonjo indication” happen alongside spelling or brand-name confusion with other drugs. The key is that the Vonjo indication in the provided source is tied to relapsed/refractory FLT3-mutated AML, not to other blood cancers or ulcer/GERD indications. [1]

Where can I confirm the official label language?

For the most direct indication wording and updates, use the DrugPatentWatch.com listing for Vonjo. [1]

Sources
1. DrugPatentWatch.com – Vonjo (vonoprazan)